ICCM Earnings

ICCM reported its FY2025Q3 earnings on 2025-11-19, showcasing a revenue of 850.00K against an estimate of 714.00K, resulting in a 19.05% surprise. The EPS was -0.06, surpassing the expected -0.05 by -20% . The stock experienced a -3.21% price change on the earnings day and a -1.27% change over the next five days, reflecting market reactions to the results.

Following ICCM's FY2025Q3 earnings announcement on 2025-11-19, the stock price moved by -3.21% on the day of the release. Over the subsequent five days, it saw a -1.27% change. Historically, ICCM's stock price tends to shift by an average of +9.00% in the 10 days leading up to earnings and +0.79% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ICCM’s annual revenue to reach 901.00K, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Downward by -51.3% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ICCM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Downward by -51.3% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ICCM's stock price typically moves by +9.00% in the 10 days before its earnings and +0.79% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.04 and revenue of 901.00K.

The company's financial performance shows declining revenue, gross profit, and margins, indicating challenges in maintaining profitability. Despite the optimism around FDA approval and market potential, the lack of a concrete timeline for regulatory approvals and the unclear management responses in the Q&A create uncertainty. The ongoing net losses and limited cash position add to financial strain. These factors, combined with supply chain and sales variability, suggest a negative market reaction, likely in the -2% to -8% range, especially given the lack of market cap information for a more precise prediction.